Cargando…

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines

Cross-feedback activation of MAPK and AKT pathways is implicated as a resistance mechanism for cancer therapeutic agents targeting either RAF/MEK or PI3K/AKT/mTOR. It is thus important to have a better understanding of the molecular resistance mechanisms to improve patient survival benefit from thes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Brenden, Tardell, Christine, Higgins, Brian, Packman, Kathryn, Boylan, John F., Niu, Huifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411810/ https://www.ncbi.nlm.nih.gov/pubmed/22880048 http://dx.doi.org/10.1371/journal.pone.0042598

Ejemplares similares

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
por: De Paolo, Raffaella, et al.
Publicado: (2023)

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition
por: Rowdo, Florencia Paula Madorsky, et al.
Publicado: (2020)

Lack of BRAFV600E mutation in stage I and II of colorectal cancer
por: Molaei, Mahsa, et al.
Publicado: (2016)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

Novel thiazole derivatives incorporating phenyl sulphonyl moiety as potent BRAFV600E kinase inhibitors targeting melanoma
por: Khormi, Afaf Y., et al.
Publicado: (2022)

Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
por: Car, Iris, et al.
Publicado: (2023)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Overproduction of thrombopoietin by BRAFV600E‐mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis
por: Tanaka, Hiroki, et al.
Publicado: (2019)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023)

Kinase Suppressor of RAS 1 (KSR1) Maintains the Transformed Phenotype of BRAFV600E Mutant Human Melanoma Cells
por: Liu, Zhi, et al.
Publicado: (2023)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
por: Satzger, Imke, et al.
Publicado: (2015)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015)

The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E‐transformed cells
por: Furlan, Tobias, et al.
Publicado: (2018)

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
por: Xue, Gongda, et al.
Publicado: (2017)

Cytotoxic Effect of Vanicosides A and B from Reynoutria sachalinensis against Melanotic and Amelanotic Melanoma Cell Lines and in silico Evaluation for Inhibition of BRAFV600E and MEK1
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2020)

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
por: Momtaz, Parisa, et al.
Publicado: (2017)

BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer
por: Toon, Christopher W, et al.
Publicado: (2014)

BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells
por: He, Kan, et al.
Publicado: (2016)

BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Silver, Jennifer A., et al.
Publicado: (2021)

Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report
por: Yunoki, Kosuke, et al.
Publicado: (2021)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
por: Subbiah, Vivek, et al.
Publicado: (2023)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
por: Giovannoni, Sara, et al.
Publicado: (2015)

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R
por: Bugide, Suresh, et al.
Publicado: (2020)

Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation
por: Poyrazoğlu, Şükran, et al.
Publicado: (2017)

DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation
por: MacKenzie, Douglas J., et al.
Publicado: (2020)

TBIO-17. INTEGRATIVE ANALYSES OF BRAFv600e MUTATED GLIOMAS: FROM MOLECULAR BIOLOGY TO RADIOLOGY AND TREATMENTS
por: Lhermitte, Benoit, et al.
Publicado: (2020)

Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
por: Hamis, Sara J., et al.
Publicado: (2021)

Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma
por: Anand, Nidhi, et al.
Publicado: (2021)

Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers
por: Ukkola, Iiris, et al.
Publicado: (2022)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
por: Lin, Yan-Yu, et al.
Publicado: (2023)

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019)

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
por: Mehnert, Janice M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_haddsiqs4obdr56on740en734k